We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amarin (AMRN - Free Report) closed at $15.02, marking a +1.49% move from the previous day. This move outpaced the S&P 500's daily loss of 1.54%. At the same time, the Dow lost 1.49%, and the tech-heavy Nasdaq lost 2.17%.
Heading into today, shares of the biopharmaceutical company had lost 14.6% over the past month, lagging the Medical sector's loss of 6.36% and the S&P 500's loss of 6.77% in that time.
AMRN will be looking to display strength as it nears its next earnings release, which is expected to be February 26, 2019. The company is expected to report EPS of -$0.08, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $66.47 million, up 23.38% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.33 per share and revenue of $218.37 million. These totals would mark changes of -32% and +20.57%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin (AMRN) Gains As Market Dips: What You Should Know
In the latest trading session, Amarin (AMRN - Free Report) closed at $15.02, marking a +1.49% move from the previous day. This move outpaced the S&P 500's daily loss of 1.54%. At the same time, the Dow lost 1.49%, and the tech-heavy Nasdaq lost 2.17%.
Heading into today, shares of the biopharmaceutical company had lost 14.6% over the past month, lagging the Medical sector's loss of 6.36% and the S&P 500's loss of 6.77% in that time.
AMRN will be looking to display strength as it nears its next earnings release, which is expected to be February 26, 2019. The company is expected to report EPS of -$0.08, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $66.47 million, up 23.38% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.33 per share and revenue of $218.37 million. These totals would mark changes of -32% and +20.57%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.